(Press-News.org) PHILADELPHIA — Dogs with hemangiosarcoma that were treated with a compound derived from the Coriolus versicolor mushroom had the longest survival times ever reported for dogs with the disease. These promising findings offer hope that the compound may one day offer cancer patients — human and canine alike — a viable alternative or complementary treatment to traditional chemotherapies.
The study was conducted by two University of Pennsylvania School of Veterinary Medicine faculty. Dorothy Cimino Brown is professor and chair of the Department of Clinical Studies and director of the Veterinary Clinical Investigation Center. Jennifer Reetz is an attending radiologist in the Department of Clinical Studies. They published their findings in an open-access article in the journal Evidence-Based Complementary and Alternative Medicine.
The Coriolus versicolor mushroom, known commonly as the Yunzhi mushroom, has been used in traditional Chinese medicine for more than 2,000 years. The compound in the mushroom that is believed to have immune-boosting properties is polysaccharopeptide, or PSP. In the last two decades, some studies have suggested that PSP also has a tumor-fighting effect.
"There have been a series of studies looking at groups of people with cancer," Cimino Brown said. "The issue with those studies is that they weren't necessarily measuring what most people would think is the most clinically important result, which is, do people taking PSP live longer?"
To address this critical question, Cimino Brown and Reetz pursued a study in dogs with naturally occurring hemangiosarcoma, an aggressive, invasive cancer that arises from the blood cells and typically affects the spleen. It commonly strikes golden retrievers and German shepherds.
Fifteen dogs that had been diagnosed with hemangiosarcoma participated in the trial. Divided into three groups of five, each group received a different dose — 25, 50 or 100 mg/kg/day — of I'm-Yunity, a formulation of PSP that has been tested for consistency and good manufacturing processes.
The owners were instructed to give their dog capsules of I'm-Yunity, compounded by Penn pharmacists, daily. Each month, the owners brought their dogs to Penn's Ryan Veterinary Hospital for follow-up visits. There, the researchers took blood samples and conducted ultrasounds to determine the extent that tumors developed or grew and spread in the dogs' bodies.
Based on the ultimate endpoints — how quickly the tumors progressed and how long the dogs actually lived — the results of the researchers' trial suggest that the I'm-Yunity was effectively fighting the tumors.
"We were shocked," Cimino Brown said. "Prior to this, the longest reported median survival time of dogs with hemangiosarcoma of the spleen that underwent no further treatment was 86 days. We had dogs that lived beyond a year with nothing other than this mushroom as treatment."
There were not statistically significant differences in survival between the three dosage groups, though the median survival time was highest in the 100 mg group, at 199 days, eclipsing the previously reported median survival time.
The results were so surprising, in fact, that the researchers asked Penn Vet pathologists to recheck the dogs' tissue biopsies to make sure that the dogs really had the disease.
"They reread the samples and said, yes, it's really hemangiosarcoma," Cimino Brown said.
Chemotherapy is available for treating hemangiosarcoma, but many owners opt not to pursue that treatment once their dog is diagnosed.
"It doesn't hugely increase survival, it's expensive and it means a lot of back and forth to the vet for the dog," Cimino Brown said. "So you have to figure in quality of life."
While I'm-Yunity is not inexpensive, if proven effective, it would offer owners a way of extending their pet's life without regular trips to the vet. As an added benefit, Cimino Brown and Reetz have found no evidence of adverse effects from the PSP treatment.
The researchers are now getting ready to pursue further trials of I'm-Yunity in dogs with hemangiosarcoma to confirm and refine their results. One trial will compare I'm-Yunity to a placebo for those owners who opt not to pursue chemotherapy in their pet and another will compare the compound to standard-of-care chemotherapy.
Depending on those results, veterinarians could eventually prescribe the compound for treating hemangiosarcoma, and perhaps other cancers, in dogs. The company that manufacturers I'm-Yunity may also pursue large-scale clinical trials in humans.
"Although hemangiosarcoma is a very sad and devastating disease," Cimino Brown said, "in the long term, if we prove that this works, this treatment can be a really nice alternative for owners to have increased quality time with their pet at the end of its life."
INFORMATION:The study was funded by a grant from Chinese Medicine Holdings LTD.
END
The fearless dominance associated with psychopathy may be an important predictor of U.S. presidential performance, suggests an analysis published this week in the Journal of Personality and Social Psychology.
"Certain psychopathic traits may be like a double-edged sword," says lead author Scott Lilienfeld, a psychologist at Emory University. "Fearless dominance, for example, may contribute to reckless criminality and violence, or to skillful leadership in the face of a crisis."
In fact, fearless dominance, linked to diminished social and physical apprehensiveness, ...
AUGUSTA, Ga. – A 10-week program that fits easily into the high school curriculum could give students a lifetime of less anger and lower blood pressure, researchers report.
Health and physical education teachers taught anger and stress management to 86 ninth graders in Augusta, Ga., and found their ability to control anger increased, their anxiety decreased and their blood pressures were generally lower over the course of a day compared to 73 of their peers who received no intervention, according to a study published in the journal Translational Behavioral Medicine.
Among ...
ANN ARBOR, Mich.—A strip of glass covered in hairy nanoparticles can cheaply and conveniently measure mercury, which attacks the nervous system, and other toxic metals in fluids.
Researchers at the Swiss Federal Institute of Technology (EPFL), Northwestern University and the University of Michigan found that their new method can measure methyl mercury, the most common form of mercury pollution, at unprecedentedly small concentrations. The system, which could test for metal toxins in drinking water and fish, is reported in the current edition of Nature Materials.
Methyl ...
Baltimore, MD – September 10, 2012 – Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the regenerative abilities of neonatal and adult-derived human cardiac stem cells. Among their findings: cardiac stem cells (CSCs) from newborns have a three-fold ability to restore heart function to nearly normal levels compared with adult CSCs. Further, in animal models of heart attack, hearts treated with neonatal stem cells pumped stronger than those ...
LA JOLLA, CA – September 10, 2012 – Over the last decade, metabolomics has emerged as the newest of the "omic" sciences (following genomics and proteomics) to provide comprehensive biochemical information about cellular metabolism. This new field has revealed that many of the chemicals involved in or produced through metabolism are currently unknown, but may play vital and previously unappreciated roles in human health and disease.
A major hurdle in profiling both unknown and known metabolic compounds ("metabolites") has been the scarce amount of reference data. But ...
TORONTO, Sept. 10, 2012—Researchers at St. Michael's Hospital are one step closer to understanding why plaque bursts in coronary arteries and causes heart attacks.
The clue might be something called microRNA-145. MicroRNAs are short chains of bossy molecules that scientists are increasingly coming to realize control a wide variety of biological processes.
Dr. Subodh Verma, a cardiac surgeon at St. Michael's, published a paper in the journal Circulation today, describing for the first time how microRNA-145 gene therapy can drastically reduce the severity and progression ...
A new kind of roof-and-attic system field-tested at the Department of Energy's Oak Ridge National Laboratory keeps homes cool in summer and prevents heat loss in winter, a multi-seasonal efficiency uncommon in roof and attic design.
The system improves efficiency using controls for radiation, convection and insulation, including a passive ventilation system that pulls air from the underbelly of the attic into an inclined air space above the roof.
"Heat that would have gone into the house is carried up and out," says Bill Miller of ORNL's Building Envelope Group. "And ...
(MEMPHIS, Tenn. – September 10, 2012) Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy.
The method uses a laboratory technique called flow cytometry, which makes it possible to identify a single cancer cell in 1,000 normal cells that remain in patient bone marrow after ...
Bethesda, MD - The Federation of American Societies for Experimental Biology (FASEB) wrote to all members of the House of Representatives expressing its opposition to the Government Spending Accountability (GSA) Act (HR 4631). While strongly supporting the bill's goal and the desire to ensure that federal agencies are using their resources responsibly and efficiently, FASEB urged Representatives to oppose the bill in its current form. FASEB President Judith S. Bond PhD expressed concern that, "if adopted, HR 4631 would impede the professional development of government ...
PHILADELPHIA — Computers may be getting faster every year, but those advances in computer speed could be dwarfed if their 1's and 0's were represented by bursts of light, instead of electricity.
Researchers at the University of Pennsylvania have made an important advance in this frontier of photonics, fashioning the first all-optical photonic switch out of cadmium sulfide nanowires. Moreover, they combined these photonic switches into a logic gate, a fundamental component of computer chips that process information.
The research was conducted by associate professor Ritesh ...
